| Generic name | Rasburicase |
| Pronunciation | raz-BYOO-ri-kase |
| Brand name(s), other common name(s) | Elitek® |
| Drug type | Antineoplastic adjunct |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Side effects needing medical attention
Signs or symptoms of an allergic reaction (chest pain, dizziness, hives, rash, trouble breathing); cracked lips; diarrhea; difficulty in swallowing; sores, ulcers or white spots on lips, tongue or inside of mouth.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.